KRAS and non-small cell lung carcinoma: In NSCLC, mutations in EGFR and KRAS have been shown to result in uncontrolled activation of PI3K/AKT/mTOR signalling, remodelling the TME, driving PD-L1 expression, and diminishing the impact of ICIs (28).